Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Open access · hybridAbstract readClinical Trial, Phase IIIAdaptive Clinical Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
17.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.Blood cancer journal · 2026Pooled it
- The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.British journal of haematology · 2024Guideline
- Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.Cancer · 2025Trial
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Blood advances · 2024Trial
- Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.American journal of hematology · 2026Article
- Article
- Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.International journal of clinical oncology · 2026Review
- Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.Blood advances · 2026Article
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
- Molecular maps of diseases from omics data and network embeddings.NPJ systems biology and applications · 2026Article
- Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma.Oncogenesis · 2026Review
- Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results.Journal of clinical medicine · 2026Article
- Optimizing first-line therapy for double-expressor lymphoma: a systematic review and meta-analysis of novel agent-augmented R-CHOP regimens.Cancer cell international · 2026Review
- Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies.Blood cancer journal · 2026Review
- Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.Cancers · 2026Review
- Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology.Blood advances · 2026Article
- The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-XBritish journal of haematology · 2026Article
- Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions.Therapeutic advances in medical oncology · 2026Review
- Proteomic Study of Diffuse Large B-Cell Lymphoma Identifying Proteins Associated with R-CHOP Response.Biomedicines · 2025Article
- Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 2 countries.
Andrew J DaviesSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-7517-6938
Sharon BarransHaematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.
Louise StantonSouthampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
Josh CaddySouthampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
Sam WildingSouthampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-4184-2821
Geoff SaundersSouthampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
Christoph MamotCantonal Hospital Aarau, Aarau, Switzerland.ORCID 0000-0002-8838-6360
Urban NovakDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0001-7642-2101
Andrew McMillanDepartment of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Paul FieldsDepartment of Haematology, Guy's and St Thomas's Hospitals NHS Trust, Kings Health Partners, London, United Kingdom.
Graham P CollinsOxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom.
Richard StephensNational Cancer Research Institute Consumer Forum, London, United Kingdom.ORCID 0000-0002-0760-2771
Francesco CuccoDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Chulin ShaSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.ORCID 0000-0001-8725-8642
Moniek van HoppeHaematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.
Reuben ToozeSection of Experimental Haematology, University of Leeds, Leeds, United Kingdom.ORCID 0000-0003-2915-7119
John R DaviesSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
Gareth GriffithsSouthampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-9579-8021
Anna SchuhDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3938-8490
Catherine BurtonHaematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.
David R WestheadSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.ORCID 0000-0002-0519-3820
Ming-Qing DuDepartment of Pathology, University of Cambridge, Cambridge, United Kingdom.
Peter W M JohnsonSchool of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0003-2306-4974
University of Southampton · GBUniversity of Leeds · GBLeeds Teaching Hospitals NHS Trust · GBUniversity of Cambridge · GBChurchill Hospital · GBKantonsspital Aarau · CHKings Health Partners · GBNational Cancer Research Institute · GBNottingham University Hospitals NHS Trust · GBUniversity of Bern · CHUniversity of Oxford · GB
Funding
Cancer Research UK 10066Cancer Research UK 12128Cancer Research UK C328/A12128
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, Large B-Cell, DiffuseAdolescentAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsBortezomibCyclophosphamideDoxorubicinFollow-Up StudiesHumansPrednisoneRetrospective StudiesRituximabVincristineAntibodies, Monoclonal, Murine-DerivedBortezomibCyclophosphamideDoxorubicinPrednisoneRituximabVincristine
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.